Neuronetics Inc (STIM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $134.10M
Last updated: Nov 17, 2026 at 11:05 AM ET
Neuronetics Inc (STIM) Stock Forecast
Analysts expect Neuronetics (STIM) to earn -$0.46 per share in the fiscal year ending Dec 31, 2026, on revenue of $162.30M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 1.75, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 25.0% |
| Buy | 3 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 9.0%.
- Fiscal year ending Dec 31, 2026
- -$0.46
- EPS consensus, revenue $162.30M
- Fiscal year ending Dec 31, 2027
- -$0.30
- EPS consensus, revenue $176.95M
- Next report
- Mar 15, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.46 | -$0.46 to -$0.45 | 3 | $162.30M | $162.00M to $162.50M | 4 |
| Dec 31, 2027 | -$0.30 | -$0.34 to -$0.26 | 3 | $176.95M | $175.70M to $178.60M | 4 |
Quarterly Estimates
The EPS consensus falls from -$0.06 for the quarter ending Dec 31, 2026 to -$0.08 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.06 | -$0.07 to -$0.05 | 6 | $45.13M | $43.12M to $46.73M | 7 |
| Mar 31, 2027 | -$0.08 | -$0.10 to -$0.07 | 3 | $37.73M | $37.50M to $37.90M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.48.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.46 | -$0.48 | -$0.48 | -$0.48 | -$0.48 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.30 | -$0.32 | -$0.32 | -$0.33 | -$0.33 | N/A |
| Quarter ending Mar 31, 2027 | -$0.08 | -$0.09 | -$0.09 | -$0.08 | -$0.08 | N/A |
Frequently Asked Questions About STIM
What is the STIM stock forecast?
Consensus analyst estimates put Neuronetics's EPS at -$0.46 for the fiscal year ending Dec 31, 2026, on revenue of $162.30M. The consensus rating from 4 analysts is Buy.
How do analysts rate STIM stock?
Of 4 analysts covering Neuronetics, 1 rates it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from STIM next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.46, with estimates from -$0.46 to -$0.45 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.30, with estimates from -$0.34 to -$0.26 from 3 analysts.
What revenue do analysts expect from Neuronetics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $162.30M, with estimates from $162.00M to $162.50M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $176.95M, with estimates from $175.70M to $178.60M.
How many analysts cover STIM?
4 analysts rate Neuronetics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
STIM pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts